Preview

Drug development & registration

Advanced search

RECOMMENDATIONS OF THE EUROPEAN PHARMACOPOEIA «ADJUSTMENT OF CHROMATOGRAPHIC CONDITIONS» AND THEIR RESTRICTIONS FOR THE METHODS OF IMPURITIES DETERMINATION

Abstract

The recommendations of admissible corrections of the chromatographic conditions provided in chapter 2.2.46 of the European Pharmacopeia in the section "Adjustment of chromatographic conditions" are examined. Based on experience of the investigation of robustness of HPLC and UPLC methods and literary data, the article points out which of these recommendations are not suitable or have significant restrictions for the methods of impurities determination. An example that confirms some of the specified restrictions is given. For methods for determining impurities, it is recommended: to use admissible corrections of the chromatographic conditions from chapter 2.2.46 of the European Pharmacopeia, in section "Adjustment of chromatographic conditions" only in the absence of closely located or partially overlapping peaks of impurities not used for control of the resolution of chromatographic system on the chromatograms of the test solution of pharmaceutical substance / drug at the end of its shelf-life or on the chromatograms of the sample solutions after stress testing; an alternative condition is the absence of such peaks on the chromatograms of the solutions obtained under stress testing with the drug substance; to set admissible limits for the change (corrections) of the chromatographic conditions on the basis of the investigation of the robustness of the methods, and to include them, if necessary, in the methods.

About the Authors

N. A. Epshtein
Autonomous Incorporation «STADA PharmDevelopment», SC «NIZHPHARM»
Russian Federation


V. L. Sevastianova
Autonomous Incorporation «STADA PharmDevelopment», SC «NIZHPHARM»
Russian Federation


A. I. Koroleva
Autonomous Incorporation «STADA PharmDevelopment», SC «NIZHPHARM»
Russian Federation


References

1. Epshtein N. A., Sevast'yanova V. L., Koroleva A. I. Robustness study in the validation of HPLC and HPLC techniques: a modern approach, including risk analysis // Development and registration of drugs. 2018. № 1(22). Р. 96-110.

2. Vander Heyden Y., Nassart D. L. Review of the use of robustness and ruggedness in analytical chemistry // Robustness of analytical chemical methods and pharmaceutical technological products / Ed. by Hendriks M.W.B., de Boer J.H., Smilde A.K. - Amsterdam: Elsevier Science B.V. 1996. P. 79-147.

3. Vander Heyden Y., Nijhuis A., Smeyers-Verbeke J. et al. Guidance for Robustness/Ruggedness Tests in Method Validation // J. Pharm. and Biomed. Analysis. 2001. V. 24. № 5-6. P. 723-753.

4. Ermer I., Miller Dzh. Kh. Validation of methods in pharmaceutical analysis. Examples of best practices. - M.: VIALEK. 2013. 495 s.

5. Method Validation in Pharmaceutical Analysis. A Guide to Best Practice / Ed. by Remer J., Miller J. H. - Wenham: Wiley-VT Verlag GmbH & Co. Ka. 2005. 403 p.

6. European Pharmacopoeia 9th ed. Chapter 2.2.46. Chromatographic separation techniques. 2017.

7. Majors R. E., Snyder L. R., Dolan J. W. Adjusting Conditions for a Routine Reversed Phase HPLC Assay. Part 2: Changing Separation Conditions // LC•GC Europe. 2005. V. 18. № 6. P. 324-329.

8. The United States Pharmacopoeia. №621> Chromatography. USP39-NF34. 2016.

9. Snyder L. R., Kirkland J. J., Glajch J. L. Practical HPLC Method Development. 2nd ed. - N.Y.: J. Wiley, 1997. P. 242.


Review

For citations:


Epshtein N.A., Sevastianova V.L., Koroleva A.I. RECOMMENDATIONS OF THE EUROPEAN PHARMACOPOEIA «ADJUSTMENT OF CHROMATOGRAPHIC CONDITIONS» AND THEIR RESTRICTIONS FOR THE METHODS OF IMPURITIES DETERMINATION. Drug development & registration. 2018;(3):182-188. (In Russ.)

Views: 935


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2305-2066 (Print)
ISSN 2658-5049 (Online)